Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.
2.

Maintenance therapy of persons with schizophrenia.

Carpenter WT Jr.

J Clin Psychiatry. 1996;57 Suppl 9:10-8. Review.

PMID:
8823345
3.

Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia.

Mallinger JB, Lamberti SJ.

J Ment Health Policy Econ. 2007 Mar;10(1):15-22.

PMID:
17417044
4.

The pharmacologic treatment of schizophrenia: a progress report.

Donaldson SR, Gelenberg AJ, Baldessarini RJ.

Schizophr Bull. 1983;9(4):504-27.

PMID:
6140750
5.

Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.

Shriqui CL.

Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S38-48. Review.

PMID:
8564916
6.

[Practical aspects of drug resistance in schizophrenia].

Jarema M, KuciƄska M.

Psychiatr Pol. 2000 Sep-Oct;34(5):721-40. Review. Polish.

PMID:
11202015
7.

Rational polypharmacy in schizophrenia.

Wolkowitz OM.

Ann Clin Psychiatry. 1993 Jun;5(2):79-90. Review.

PMID:
8348207
8.

[Associated psychotropic drugs in deficit schizophrenia].

Beaufils B.

Encephale. 1996 Jun;22 Spec No 2:41-3. Review. French.

PMID:
8767041
9.

Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia.

Galletly CA, Tsourtos G.

Ann Clin Psychiatry. 1997 Jun;9(2):77-80.

PMID:
9242892
10.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
11.

Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia.

Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA.

Psychopharmacol Bull. 1992;28(3):291-5. Review.

PMID:
1362277
12.

Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy.

Johns CA, Thompson JW.

Schizophr Bull. 1995;21(4):607-19. Review.

PMID:
8749888
13.

Rational polypharmacy in the bipolar affective disorders.

Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, Leverich G, Frye M.

Epilepsy Res Suppl. 1996;11:153-80. Review.

PMID:
9294735
14.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

15.

Management of treatment resistance in schizophrenia.

Conley RR, Kelly DL.

Biol Psychiatry. 2001 Dec 1;50(11):898-911. Review.

PMID:
11743944
16.

Management of treatment-resistant patients with schizophrenia.

Marder SR.

J Clin Psychiatry. 1996;57 Suppl 11:26-30. Review.

PMID:
8941168
17.

Benzodiazepines in schizophrenia.

Stimmel GL.

Pharmacotherapy. 1996 Nov-Dec;16(6 Pt 2):148S-151S; discussion 166S-168S. Review.

PMID:
8947998
18.

An open trial of adjunctive sertraline in the treatment of chronic schizophrenia.

Thakore JH, Berti C, Dinan TG.

Acta Psychiatr Scand. 1996 Sep;94(3):194-7.

PMID:
8891087
19.

Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia.

Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D.

Psychopharmacol Bull. 1989;25(2):263-6. No abstract available.

PMID:
2574897
20.

Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?

Citrome L.

Expert Rev Neurother. 2009 Jan;9(1):55-71. doi: 10.1586/14737175.9.1.55. Review.

PMID:
19102669

Supplemental Content

Support Center